ERBB2 and breast cancer: This study aimed to develop and validate a dedicated preoperative nomogram for predicting apCR in human epidermal growth factor receptor 2 (HER2)-positive BC using readily available clinical variables and to further evaluate the prognostic significance of apCR for survival outcomes within our cohort.<h4>Methods</h4>This retrospective study enrolled 189 patients with initially node-positive, HER2-positive BC who received NAT and anti-HER2 targeted therapy.